Patient‐reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma

Key Points

• To assess the impact of adding trastuzumab on patient-reported outcomes (PROs) in localized HER2+ esophageal adenocarcinoma.
• Phase 3 trial design
• Inclusion of patients with HER2 overexpressing esophageal adenocarcinoma
• Comparison of PROs between groups receiving and not receiving trastuzumab
• No improvement in patient-reported outcomes with the addition of trastuzumab to combined radiation therapy.